Celebrating 25 years Est 1999-2024
*Across 3 years $3395.52 only $1697.76
Keryx Biopharmaceuticals Adds Three Clinical-Stage Oncology Drug Candidates to its Pipeline, Including a Novel, First-in-Class, Oral AKT-Inhibitor...
Keryx Biopharmaceuticals, Inc. News NEW YORK, Dec. 19 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; AIM: KRX), today announced that application...
Keryx Biopharmaceuticals, Inc. News NEW YORK, Nov. 26 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; AIM: KRX), today announced that...
Keryx Biopharmaceuticals, Inc. Announces S.O.A.R. (Sulodexide Open Access Research) Program Collaboration with the University of Michigan Top...
Keryx Biopharmaceuticals, Inc. Raises $15 Million In Private Equity Transaction With Institutional Investors NEW YORK, Nov. 18 / -- Keryx...
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2003 Financial Results - Keryx to Hold Investor Conference Call Tomorrow, Tuesday, November...
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2003 Financial Results on Tuesday, November 11, at 10:00 a.m. EST NEW...
REMINDER: Keryx Biopharmaceuticals CEO to Provide KRX-101 Update Today at the Rodman & Renshaw Techvest Healthcare Conference NEW YORK, Oct. 21...
Keryx Biopharmaceuticals, Inc. Initiates Phase II/III Clinical Program of KRX-101 (Sulodexide Gelcaps) for Treatment of Diabetic Nephropathy...
Keryx Biopharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference NEW YORK, Oct. 16 -- Keryx Biopharmaceuticals, Inc...
Keryx Biopharmaceuticals, Inc. Announces S.O.A.R. (Sulodexide Open Access Research) Program Collaboration with National Institutes of Health for...
Keryx Biopharmaceuticals to Present at UBS Warburg Global Life Sciences Conference NEW YORK, Sept. 18 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:...
Keryx Biopharmaceuticals, Inc. Announces First S.O.A.R. (Sulodexide Open Access Research) Program Collaboration for KRX-101 Esteemed Researcher to...
Keryx Biopharmaceuticals, Inc. to Present at The Bear Stearns 16th Annual Healthcare Conference NEW YORK, Sept. 5 -- Keryx Biopharmaceuticals...
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2003 Financial Results - Keryx to Hold Investor Conference Call Tomorrow, Thursday, August...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.